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Contrary to national guidelines, in the mid-2000s in England and Wales, prescribed doses 
of the heroin substitute methadone were generally low, and often even new patients 
were not required to take it under supervision at the pharmacy. Patients in Essex also 
generally favoured low doses and opposed supervised consumption.
Summary Based on data from the mid-2000s, this report relates the findings of a survey 
of usual prescribing practices at NHS community drug teams in England and Wales 
(which treat addiction to drugs including heroin) to a companion survey of the opinions 
on these policies of patients from one area.
Prescribing practices
In 2004 and 2005 a postal questionnaire was sent to the prescribing doctor at each of 
the 140 community drug teams in England and Wales, supplemented by phone calls to 
team managers to determine further details of their prescribing practices and policies. 
Responses were received from 120 of the teams. 
All but 3% of the services which responded could arrange supervised consumption of 
methadone either through an on-site dispensary or at local pharmacies. However, 22% of 
teams said fewer than half the methadone patients starting treatment were supervised. 
In 45% of teams fewer than 10 patients were on methadone doses exceeding 60mg a 
day. All but 3% of teams prescribed buprenorphine to opiate-dependent patients. Six in 
ten prescribed benzodiazepines only for alcohol detoxification. One in four would 
prescribe these drugs on a maintenance basis, though only four teams did so for more 
than 10 patients. Injectable medications had been prescribed by 24% of teams, but only 
two had over 10 patients on these formulations.
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Patients' views
At the time the drug and alcohol services of the South Essex Partnership NHS Trust 
treated about 1300 patients at four community drug teams in South East England, of 
whom about 600 were prescribed methadone or buprenorphine. Over half the methadone 
patients received doses between 30 and 60mg a day and fewer than 10 over 80mg. Over 
9 in 10 initiated methadone treatment on supervised consumption for at least three 
months.
The views of the patients on prescribing policies in general (not at their particular 
service) were assessed in 2005 via questionnaires offered by receptionists and 
prescribing doctors to all patients being prescribed methadone or buprenorphine. 104 
responded. About three quarters were men, 15% were employed, and nearly 9 in 10 had 
left full-time education aged 16 or younger.
Asked "What do you think is the maximum dose of oral methadone that should be 
prescribed to people who are addicted to heroin?", just 10% thought there should be no 
limit; most (53%) opted for a limit of up to either 60mg or 80mg. They were told that UK 
guidelines recommended methadone "should be taken in front of a pharmacist each 
weekday for at least 3–6 months" and asked if they agreed; 52% disagreed, 34% 
agreed. Two thirds said benzodiazepines should only be prescribed as part of a reducing 
regimen and then only with daily collection.
The authors' conclusions
Relatively low doses of methadone remain the norm in England and Wales and contrary 
to national guidance, a sizable minority of clients were still started on methadone to take 
away. Buprenorphine was almost universally available. Community drug teams were 
reluctant to prescribe injectables or to offer benzodiazepines other than for alcohol 
withdrawal. Patients in opiate substitution treatment in Essex were generally opposed to 
supervised consumption of methadone, but otherwise tended to support rather 
conservative prescribing policies. More below.
Despite guidelines to the contrary, and the dangers of diverted methadone, a fifth of 
patients started on methadone are prescribed it to take away, and the proportion is likely 
to be much higher among long-term patients. Recently the same authors had phoned 
1000 pharmacies throughout England and discovered that two-thirds of patients were 
prescribed methadone to take away. Historical practice and the reluctance of many 
British pharmacies to provide the required facilities make routine supervised consumption 
of methadone difficult to provide. Since just over half the service users asked were 
opposed to supervised consumption, community drug teams may also be under pressure 
from service users to permit methadone to be dispensed to take away.
A potential compromise is to prescribe lower doses so methadone can more safely be 
taken away. Nationally about half community drug teams had fewer than 10 patients on 
doses over 60mg methadone daily. Low dosing is supported by service users in Essex, 
just over half of whom said doses should not exceed 80mg. There are persistent concerns 
that doses in the UK are suboptimal for the patients. On the other hand, higher doses 
create a potentially serious risk to other drug users when sold on the black market. Other 
reasons for low doses might be a preference for detoxification rather than maintenance; 
at a London clinic, asked whether outpatient detoxification or maintenance was most 
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likely to stop them using street heroin, 60% of patients opted for detoxification, contrary 
to evidence from research. Low doses may also be due to the number of inexperienced 
doctors in addiction treatment, or the experience of many workers that modest doses of 
methadone (up to 60mg) do prevent illicit opiate use in many clients. Patients 
themselves do not agree with the prescription of very high doses of methadone, so there 
may be little demand from them for these levels.
The reluctance of community drug teams to prescribe benzodiazepines on a maintenance 
basis was supported by the patients in the survey, as was caution over prescribing 
injectables.
In interpreting these findings it should be remembered that patients self-selected 
whether to complete the survey; about 1 in 6 of all those prescribed methadone or 
buprenorphine at the four clinics did so.
 The persistence of unsupervised methadone prescribing in England and 
Wales (less so in Scotland) is unusual internationally and is also where the preferences of 
patients (generally against) and national guidance (in favour at the start of treatment) 
most obviously diverge. The approach has yet to be subject to large scale research in 
Britain. This was one of the intentions of the NTORS study of addiction treatment in 
England which recruited its patients in 1995. The closest the study came to reporting the 
findings was a comparison between seven GP-led methadone services and eight specialist 
clinics. The major difference in their prescribing practices was that three quarters of the 
clinics required patients to take their methadone under supervision, but just one of the 
GP programmes. Two years after entering treatment, GP and clinic patients had improved 
substantially and to roughly the same degree, but what differences there were favoured 
the GPs. GP patients had made significantly greater reductions in use of stimulants and 
non-prescribed benzodiazepines and greater gains in psychological health. They also 
tended to stay in treatment longer.
Additionally, a small scale Scottish study randomly allocated 60 patients to supervised 
consumption. However, all had already been in supervised treatment for about three 
months so the relaxation did not breach guidelines. For the next three months they either 
stopped being supervised (but still had to collect their medication daily) or were 
supervised daily or twice weekly. Unsupervised patients were most likely to stay in 
treatment, those supervised daily to leave. Among the 46 who could be reassessed, illicit 
heroin use was rare before the switch (one or two days a month) and remained rare at 
the end, though with slight reductions among the supervised patients and a slight 
increase among the unsupervised. None of these differences between outcomes under 
the three supervision regimens were substantial or statistically significant. There was 
however a clear divide in patient reactions. Two-thirds of those relieved of the need to 
take their medication at the pharmacy were happy about their allocation, but only 30% 
subject to twice-weekly supervision and 14% daily. Given the chance to express their 
views in their own words, the unsupervised patients highlighted reduced stigma, the 
supervised patients, the continued stigma of being exposed as a methadone patient at 
the pharmacy.
An important reason for supervising consumption is to prevent methadone being sold on 
the illicit market or otherwise 'diverted' to people other than the patient for whom it was 
intended, with possibly fatal consequences in the form of opioid overdose. A study of 
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methadone overdoses in Scotland and England suggests these concerns are valid and 
that supervision does have the desired impact. It concluded that declines in the per-dose 
rate of deaths due to methadone overdose were due to the spread of supervised 
consumption, the main reason for a remarkable improvement in the safety of methadone 
prescribing from 1995 to 2004. However, the study was unable to determine whether 
each opiate user in or out of treatment had become more or less likely to survive as a 
result of the introduction of supervised consumption. Supervision should also help 
prevent elevated death rates in the first few weeks of treatment because clinicians can 
monitor the patients more closely and directly control their methadone intake. It also 
means the prescriber can be sure that the drug has been taken and that therefore the 
patient has built up the required tolerance to make such doses safe, and helps assess 
whether higher doses are required and would be safe. The structure and contact it 
imposes can also be therapeutic.
Set against this, to the degree that (as some clinicians believe) the supervision 
requirement causes dependent opiate users to avoid treatment it would prevent 
substitute prescribing realising its lifesaving potential. As suggested by the Scottish study 
referred to above, some studies have also reported that patients find it difficult to comply 
with long-term attendance or supervision requirements, leading to reduced compliance 
with treatment and premature drop-out or discharge, impacts which would again reduce 
the treatment's benefits via reduced retention. How these contrary influences balance out 
to affect overdose on opiate-type drugs as a whole – heroin as well as methadone – is 
unclear.
For a similar but later survey of services in Scotland see this Findings analysis. For a summary of research on 
these and related issues see this Findings review. Other analyses related to supervised consumption can be 
found by running this search.
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